​

ADMA Biologics (ADMA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADMA Stock Forecast

ADMA Biologics (ADMA) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $16.00, with a high of $18.00 and a low of $14.00. This represents a -25.93% decline from the last price of $21.60.

- $5 $10 $15 $20 $25 High: $18 Avg: $16 Low: $14 Last Closed Price: $21.6

ADMA Stock Rating

ADMA Biologics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 1 Strong Buy (11.11%), 8 Buy (88.89%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 8 1 Strong Sell Sell Hold Buy Strong Buy

ADMA Price Target Upside V Benchmarks

TypeNameUpside
StockADMA Biologics-25.93%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$16.00
Last Closing Price$21.60$21.60$21.60
Upside/Downside---25.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-21--3
May, 25-31--4
Apr, 25-4---4
Mar, 25-4---4
Feb, 25-4---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2024Raghuram SelvarajuH.C. Wainwright$18.00$17.154.96%-16.67%
Jun 20, 2024Anthony PetroneMizuho Securities$14.00$10.6231.83%-35.19%
Jan 03, 2023H.C. Wainwright$4.50$3.8815.98%-79.17%
Nov 10, 2022Mizuho Securities$6.00$3.0596.72%-72.22%
Jul 25, 2022H.C. Wainwright$4.00$2.1784.33%-81.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024Cantor FitzgeraldUnderperformUnderperformhold
Oct 14, 2024H.C. WainwrightBuyBuyhold
Sep 20, 2024Cantor FitzgeraldBuyBuyhold
Aug 12, 2024H.C. WainwrightBuyBuyhold
Jul 09, 2024Cantor FitzgeraldOverweightOverweighthold
May 10, 2024Raymond JamesStrong BuyStrong Buyhold
May 10, 2024Cantor FitzgeraldOverweightOverweighthold
May 10, 2024H.C. WainwrightBuyBuyhold
Feb 29, 2024Cantor FitzgeraldUnderperformUnderperformhold
Jan 22, 2024Cantor FitzgeraldUnderperformUnderperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.02$-0.61$-0.43$-0.13$0.85----
Avg Forecast$-0.84$-0.51$-0.33$-0.02$0.51$0.68$0.84$1.02$1.34
High Forecast$-0.83$-0.50$-0.32$-0.02$0.52$0.69$0.98$1.24$1.36
Low Forecast$-0.86$-0.52$-0.35$-0.02$0.50$0.66$0.76$0.88$1.33
Surprise %21.43%19.61%30.30%550.00%66.67%----

Revenue Forecast

$0 $170M $340M $510M $680M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$42.22M$80.94M$154.08M$258.21M$426.45M----
Avg Forecast$41.07M$76.24M$151.48M$256.45M$421.67M$479.20M$599.10M$712.23M$840.03M
High Forecast$41.65M$77.32M$156.91M$258.35M$424.78M$482.74M$603.53M$739.74M$846.24M
Low Forecast$40.52M$75.22M$147.98M$254.97M$419.23M$476.43M$595.63M$684.72M$835.17M
Surprise %2.79%6.16%1.72%0.69%1.14%----

Net Income Forecast

$-200M $-90M $20M $130M $240M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-87.61M$-84.45M$-85.18M$-28.24M$197.67M----
Avg Forecast$-188.70M$-114.93M$-60.18M$-28.24M$113.48M$151.94M$195.24M$237.69M$300.88M
High Forecast$-185.40M$-112.92M$-48.14M$-22.59M$115.71M$155.27M$220.53M$278.32M$303.77M
Low Forecast$-192.15M$-117.03M$-72.21M$-33.89M$111.26M$148.61M$169.95M$197.06M$298.61M
Surprise %-53.57%-26.52%41.56%-74.19%----

ADMA Forecast FAQ

Is ADMA Biologics stock a buy?

ADMA Biologics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ADMA Biologics is a favorable investment for most analysts.

What is ADMA Biologics's price target?

ADMA Biologics's price target, set by 9 Wall Street analysts, averages $16 over the next 12 months. The price target range spans from $14 at the low end to $18 at the high end, suggesting a potential -25.93% change from the previous closing price of $21.6.

How does ADMA Biologics stock forecast compare to its benchmarks?

ADMA Biologics's stock forecast shows a -25.93% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for ADMA Biologics over the past three months?

  • June 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 75.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ADMA Biologics’s EPS forecast?

ADMA Biologics's average annual EPS forecast for its fiscal year ending in December 2025 is $0.68, marking a -20.00% decrease from the reported $0.85 in 2024. Estimates for the following years are $0.84 in 2026, $1.02 in 2027, and $1.34 in 2028.

What is ADMA Biologics’s revenue forecast?

ADMA Biologics's average annual revenue forecast for its fiscal year ending in December 2025 is $479.2M, reflecting a 12.37% increase from the reported $426.45M in 2024. The forecast for 2026 is $599.1M, followed by $712.23M for 2027, and $840.03M for 2028.

What is ADMA Biologics’s net income forecast?

ADMA Biologics's net income forecast for the fiscal year ending in December 2025 stands at $151.94M, representing a -23.14% decrease from the reported $197.67M in 2024. Projections indicate $195.24M in 2026, $237.69M in 2027, and $300.88M in 2028.